Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY25 results · Apr–Jun 2024
Astec LifeSciences reported revenue from operations of ₹69.37 crore (down 51.4% from Q1 FY24) and net loss of ₹39.72 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 69.37 | 142.85 | −51.4% | 153.75 | −54.9% |
| Other income | 0.92 | 1.71 | −45.9% | 2.05 | −54.9% |
| Total income | 70.30 | 144.56 | −51.4% | 155.80 | −54.9% |
| Profit before tax | (61.64) | (11.01) | Loss widened | (0.93) | Loss widened |
| Net profit for the period | (39.72) | (8.19) | Loss widened | (0.96) | Loss widened |
| Attributable to shareholders of the company | (39.72) | (8.19) | Loss widened | (0.97) | Loss widened |
| EPS, basic (₹) | (20.26) | (4.18) | Loss widened | 0.50 | Turned loss |
| Net margin (%) | -57.2 | -5.7 | -0.6 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 69.37 | 142.85 | −51.4% | 153.75 | −54.9% |
| Other income | 0.91 | 1.70 | −46.6% | 2.03 | −55.4% |
| Total income | 70.28 | 144.55 | −51.4% | 155.78 | −54.9% |
| Profit before tax | (61.67) | (11.03) | Loss widened | (0.96) | Loss widened |
| Net profit for the period | (39.74) | (8.21) | Loss widened | (0.99) | Loss widened |
| EPS, basic (₹) | (20.26) | (4.19) | Loss widened | 0.50 | Turned loss |
| Net margin (%) | -57.3 | -5.7 | -0.6 |
Consolidated
- Filed with BSE
- 20 Aug 2024, 17:03 IST
- Board meeting
- 29 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Aug 2024, 17:03 IST
- Board meeting
- 29 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE